Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Rebecq – page 83

1 850 clinical trials in Rebecq, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Rebecq at a glance
1 850
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 850 trials in Rebecq

Open in trial search

Obesity

Not recruiting

Zenagamtide for Weight Loss in Adults with Obesity

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Ovarian cancer

Not recruiting

Phase 3 Study of INCB123667 versus investigator's choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:INCB123667
  • Sponsor:Incyte Corp.

Multiple sclerosis

Not recruiting

A study to compare the effectiveness and safety of subcutaneous frexalimab versus intravenous frexalimab in adults with multiple sclerosis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Amgen Inc.

Bronchiectasis

Not recruiting

A study to evaluate the safety and effectiveness of AZD0292 in people aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa infection

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:AZD0292
  • Sponsor:AstraZeneca AB

Colitis ulcerative

Not recruiting

A study to evaluate the efficacy and safety of vixarelimab in patients with moderate to severe ulcerative colitis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Genentech Inc.

Study of tarlatamab and durvalumab compared to durvalumab alone for patients with extensive stage small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Amgen Inc.

Pericarditis

Not recruiting

A study to evaluate the safety and effectiveness of VTX2735 sodium in patients with recurrent pericarditis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:VTX2735 sodium
  • Sponsor:Zomagen Biosciences Limited

Cervix carcinoma+1

Not recruiting

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

COVID-19

Not recruiting

A study of the effects of nirmatrelvir, ritonavir, and rosuvastatin in healthy adult participants

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Nirmatrelvir
  • Sponsor:Pfizer Inc.

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cobolimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Evaluation of safety and efficacy of 19CP02 combined with cyclophosphamide and fludarabine phosphate in adults with treatment‑refractory active systemic lupus erythematosus

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Lakefront Biotherapeutics

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Rebecq

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) de-prescribing strategies for patients with chronic usage patterns. This research aims to optimize medication management for individuals with functional dyspepsia and reflux-related conditions.

  • PPI Usage Optimization
  • Digestive Health Management
  • Medication De-prescribing Strategies

The research evaluates different approaches including on-demand usage and alternative treatments, aimed at improving patient care in primary healthcare settings.

02 Primary Care Medicine

Studies examining long-term medication management practices in primary care, with a focus on gastrointestinal disorders and symptom control. This research explores alternative treatment approaches for common digestive complaints.

  • Treatment Optimization
  • Alternative Therapy Evaluation
  • Patient-Centered Care

The research compares various therapeutic strategies to identify the most effective approach for managing chronic digestive conditions in primary care settings.

03 Clinical Therapeutics

Investigation into medication discontinuation strategies, focusing on long-term acid suppression therapy. This research evaluates the effectiveness of different approaches to reducing medication dependence while maintaining symptom control.

  • Therapeutic Alternative Assessment
  • Symptom Management
  • Treatment Efficacy Comparison

The study compares conventional dose reduction methods with newer therapeutic approaches to optimize patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.